

*Sub
C 5
com.*

7. (Amended) The composition of claim 6, wherein the β -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.

*Sub
C 5 B7*

10. (Amended) The composition of claim 9 formulated to be administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.

*Sub
C 5 B7*

14. (Amended) The method of claim 13, wherein the β -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.

15. (Amended) The method of claim 14, wherein the composition is administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.

B7

22. (Twice amended) The method of claim 15, wherein the composition is administered in the form of a tablet.

Please add the following new claims:

*Sub
C 5 B7*

36. (New) A pharmaceutical composition for treating endometriosis comprising:
(i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
and
(ii) polycarbophil.

37. (New) A pharmaceutical composition for treating infertility or improving fertility comprising:
(i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
and
(ii) polycarbophil.

REMARKS

Claims 1-10 and 13-22, as amended, and new claims 36-37, are pending in this application for the Examiner's review and consideration. A marked up version of the